Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A.
N05AE05
lurasidone
Psycholeptics
Schizophrenia
Treatment of schizophrenia in adults aged 18 years and over.
Revision: 25
Authorised
2014-03-21
37 B. PACKAGE LEAFLET 38 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LATUDA 18.5 MG FILM-COATED TABLETS LATUDA 37 MG FILM-COATED TABLETS LATUDA 74 MG FILM-COATED TABLETS lurasidone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Latuda is and what it is used for 2. What you need to know before you take Latuda 3. How to take Latuda 4. Possible side effects 5. How to store Latuda 6. Contents of the pack and other information 1. WHAT LATUDA IS AND WHAT IT IS USED FOR Latuda contains the active substance lurasidone and belongs to a group of medicines called antipsychotics. It is used to treat symptoms of schizophrenia in adults (aged 18 years and over) and adolescents aged 13-17 years. Lurasidone works by blocking receptors in the brain to which the substances dopamine and serotonin attach. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) that are involved in the symptoms of schizophrenia. By blocking their receptors, lurasidone helps to normalise the activity of the brain, reducing the symptoms of schizophrenia. Schizophrenia is a disorder with symptoms such as hearing things, seeing or sensing things that are not there, mistaken beliefs, unusual suspiciousness, becoming withdrawn, incoherent speech and behaviour and emotional flatness. People with this disorder may also feel depressed, anxious, guilty, or tense. This medicine is used to improve your symptoms of schizophrenia. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LATUDA DO NOT TAKE Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Latuda 18.5 mg film-coated tablets Each film-coated tablet contains lurasidone hydrochloride equivalent to18.6 mg lurasidone. Latuda 37 mg film-coated tablets Each film-coated tablet contains lurasidone hydrochloride equivalent to 37.2 mg lurasidone. Latuda 74 mg film-coated tablets Each film-coated tablet contains lurasidone hydrochloride equivalent to 74.5 mg lurasidone. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Latuda 18.5 mg film-coated tablets White to off-white, film-coated round tablets of 6 mm debossed with ‘LA’ Latuda 37 mg film-coated tablets White to off-white, film-coated round tablets of 8 mm debossed with ‘LB’ Latuda 74 mg film-coated tablets Pale green, film-coated oval tablets of 12 mm x 7 mm debossed with ‘LD’ 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Latuda is indicated for the treatment of schizophrenia in adults and adolescent aged 13 years and over. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adult population_ The recommended starting dose is 37 mg of lurasidone once daily. No initial dose titration is required. It is effective in a dose range of 37 to 148 mg once daily. Dose increase should be based on physician judgement and observed clinical response. The maximum daily dose should not exceed 148 mg. Patients on doses higher than 111 mg once daily who discontinue their treatment for longer than 3 days should be restarted on 111 mg once daily and up-titrated to their optimal dose. For all other doses patients can be restarted on their previous dose without need for up-titration. _Paediatric population_ The recommended starting dose is 37 mg of lurasidone once daily. No initial dose titration is required. It is effective in a dose range of 37 to 74 mg once daily. Dose increase should Lue koko asiakirja